TY - JOUR
T1 - Exploring the potential of mealworm chitosan for hemodialysis applications
AU - Martingo, Maria
AU - Baptista-Silva, Sara
AU - Mesquita, Raquel
AU - Ferreira, João Paulo
AU - Borges, Sandra
AU - Pintado, Manuela
N1 - Publisher Copyright:
© 2025 The Authors
PY - 2025/6
Y1 - 2025/6
N2 - This study introduces a sustainable and efficient alternative to traditional chitosan sources derived from crustaceans, exploring the extraction and application of insect-derived chitosan from Tenebrio molitor for hemodialysis (HD) membranes design. Efficient extraction and deacetylation methods were tested and developed between 6 h and 12 h to obtain chitosan. Chitin was isolated from T. molitor through deproteinization and demineralization, with yields of approximately 5 % (w/w). Chitosan was obtained from the extracted chitin resulting in yields of between 65.0 and 79.3 (w/w). Characterization using FTIR confirmed structural similarities with commercial chitosan and degrees of deacetylation in the 73–75 % range. The bioactive properties of chitosan obtained from T. molitor, including antimicrobial and antioxidant activities, were evaluated. All the microorganisms tested were inhibited, exhibiting minimum lethal concentrations between 2 and 8 mg/mL. In addition, chitosan showed antioxidant activity in the range of 60–65 μmol Trolox equivalent/g, suggesting its viability for various medical applications. This study additionally allowed the design of sustainable hybrid chitosan membrane (CH-M) tailored for HD applications. The permeation characteristics of CH-M for urea and albumin were studied in vitro to assess their suitability as HD membranes. Urea was permeable to values of over 70 % and albumin was retained. Also, cytotoxicity assays against L929 fibroblast cells demonstrated that the CH-M samples exhibit low metabolic inhibition (around 15 %) The application of CH-M in HD represents a significant advance, offering the potential for enhanced therapeutic outcomes for chronic kidney disease (CKD).
AB - This study introduces a sustainable and efficient alternative to traditional chitosan sources derived from crustaceans, exploring the extraction and application of insect-derived chitosan from Tenebrio molitor for hemodialysis (HD) membranes design. Efficient extraction and deacetylation methods were tested and developed between 6 h and 12 h to obtain chitosan. Chitin was isolated from T. molitor through deproteinization and demineralization, with yields of approximately 5 % (w/w). Chitosan was obtained from the extracted chitin resulting in yields of between 65.0 and 79.3 (w/w). Characterization using FTIR confirmed structural similarities with commercial chitosan and degrees of deacetylation in the 73–75 % range. The bioactive properties of chitosan obtained from T. molitor, including antimicrobial and antioxidant activities, were evaluated. All the microorganisms tested were inhibited, exhibiting minimum lethal concentrations between 2 and 8 mg/mL. In addition, chitosan showed antioxidant activity in the range of 60–65 μmol Trolox equivalent/g, suggesting its viability for various medical applications. This study additionally allowed the design of sustainable hybrid chitosan membrane (CH-M) tailored for HD applications. The permeation characteristics of CH-M for urea and albumin were studied in vitro to assess their suitability as HD membranes. Urea was permeable to values of over 70 % and albumin was retained. Also, cytotoxicity assays against L929 fibroblast cells demonstrated that the CH-M samples exhibit low metabolic inhibition (around 15 %) The application of CH-M in HD represents a significant advance, offering the potential for enhanced therapeutic outcomes for chronic kidney disease (CKD).
KW - Bio-based membrane
KW - Chitosan
KW - Hemodialysis treatment
KW - Tenebrio molitor
UR - http://www.scopus.com/inward/record.url?scp=105001872230&partnerID=8YFLogxK
U2 - 10.1016/j.scp.2025.102013
DO - 10.1016/j.scp.2025.102013
M3 - Article
AN - SCOPUS:105001872230
SN - 2352-5541
VL - 45
JO - Sustainable Chemistry and Pharmacy
JF - Sustainable Chemistry and Pharmacy
M1 - 102013
ER -